KPV
A consistent animal file and an empty human one: no study of KPV in a person exists.
D
Evidence grade
D
Worth it
$50-100/month
Typical cost
DoseNo validated human dose exists. KPV is sold as oral capsules, nasal spray, and topical products at seller-set doses; none of them comes from a human study, because no human study exists.
BasisKPV is the three-amino-acid tail of alpha-MSH (lysine, proline, valine).
KPV is a tripeptide, the lysine-proline-valine tail of alpha-MSH, the melanocortin hormone fragment it is cut from. We grade KPV D on evidence and D for worth-it at about $50-100 per month.
What it does
KPV is a tripeptide, the lysine-proline-valine tail of alpha-MSH, the melanocortin hormone fragment it is cut from. It is sold for gut inflammation, leaky gut, and skin inflammation, and blended into multi-peptide products. In cell and animal work it dampens NF-kB signaling and the inflammatory cytokines downstream of it, and an intestinal transporter (PepT1) gives oral delivery a plausible route in an inflamed colon. Everything past that paragraph is extrapolation: the human evidence base for KPV is empty.
What the research says
Reduces gut inflammation (leaky gut, colitis)
Evidence: weak. The preclinical file is genuinely consistent: KPV reduces NF-kB signaling and inflammatory cytokines in cell work and reduces colitis severity across several rodent models (Kannengiesser 2008; Dalmasso 2008, Gastroenterology, which identified the PepT1 transporter as the route that makes oral delivery plausible in an inflamed colon). The human file is empty: no published human trial of KPV exists for any indication, by any route.
Calms skin inflammation
Evidence: weak. Sold for skin inflammation on the same animal and cell evidence as the gut claim. No human efficacy, pharmacokinetic, or formal safety study exists for the skin use either.
KPV is the three-amino-acid tail of alpha-MSH (lysine, proline, valine). Its preclinical file is genuinely consistent, across cell work and several rodent colitis models. Its human file is empty: there is no published human trial of KPV for any indication, by any route, no efficacy study, no pharmacokinetic study, no formal safety study. The FDA's 2026 review, run ahead of the Pharmacy Compounding Advisory Committee's July 2026 vote, searched the literature and adverse event databases and found no study of KPV administered to a human at all; the committee voted 8 to 6 to recommend adding KPV to the compounding list anyway, against the FDA scientists' recommendation, and that vote is not evidence. Under the house standard (human trial evidence only), a compound with zero human data grades D, the same grade as MOTS-c and epithalon, and for the same stated reason; BPC-157 grades D as well, on a human file that reaches no further than a two-person uncontrolled pilot with no efficacy endpoint, with no human randomized or efficacy trial behind it.
Is it worth it?
Evidence (D) sits below the evidence bar for the ranking, so the worth-it grade is capped at C+ however inexpensive it is; at about $75 a month the derived value lands at D. There is no human study behind the purchase at any price.
Typical cost
$50-100/month
Common form, not a brand recommendation
Dosage context no established dose
No validated human dose exists. KPV is sold as oral capsules, nasal spray, and topical products at seller-set doses; none of them comes from a human study, because no human study exists.
The worth-it ranking
KPV sits outside the worth-it ranking of 38.
KPV sits outside that ranking of 38. The leaders below clear an evidence floor of B- before price counts at all, so cheap alone never earns a rank.
- 1AWorth itCreatine evidence A-~$5-10/mo
- 2AWorth itCaffeine evidence B+~$5-10/mo
- 3AWorth itVitamin D evidence B~$5-8/mo
When the evidence moves a grade, this ranking moves with it. Thursday is where you hear it first.
Safety notes
The honest safety note for this class: there are no reported human harms because no one has run the study that would find them. No formal toxicology or pharmacokinetic work exists in humans, and research-grade supply sits outside pharmaceutical quality controls, so purity and dose accuracy are the seller's word. Talk to your doctor. This page is information, not medical advice.
Changelog
Last updated 2026-11-12
- 2026-11-12|Initial grading: Research's weekly deep dive of 2026-11-02 (KPV section), integrated on its ruled slot (Nov 12, the grade-first promotable behind the dated set and cinnamon). Evidence D on an empty human file, the MOTS-c shape: the grade describes the human evidence, not the promise of the animal work. This library never recommends KPV at any experience level; it is graded here because readers already take it, and the grade is the verdict.
The week's longevity and biohacking news.
Every story graded against the evidence. Free. Unsubscribe anytime.
The week's longevity and biohacking news. Every story graded against the evidence. Free. Unsubscribe anytime.
Every grade follows a published rubric. Sponsors do not influence findings or grades.